Contingency

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, March 29, 2024
Retina, Chair, Three Months, Biologics license application, Secretome, Disease, Infection, Incidence, Paratriathlon, Inflammation, Patient, Sale, Limbal stem cell, Research, CIRM, Acquisition, Commercial, Eye, Safety, Retinitis pigmentosa, Food, FDA, BLA, Stargardt disease, Physician, Contingency, Protease, Cryptocurrency

ARLINGTON, Mass., March 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • “In 2023, we focused on clinical execution, advancing our Phase 2b CHASE trial of KPI-012 for the treatment of PCED.
  • In December 2023 and March 2024, KALA announced private placement financings with an institutional investor, priced at-the-market under Nasdaq rules.
  • Cash Position: As of December 31, 2023, KALA had cash and cash equivalents of $50.9 million, compared to $56.1 million as of September 30, 2023.
  • Operating Loss: For the quarter ended December 31, 2023, loss from operations was $9.6 million, compared to $10.3 million for the same period in 2022.

ESS Tech, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 13, 2024
Other Manufacturing, Environment, Technology, Other Energy, Engineering, Alternative Energy, Manufacturing, Green Technology, Energy, Batteries, Nexus, Energy Centre, Forward, Interest, EW, Partnership, Telephone, Reefer ship, Honeywell, EDT, TID, Contingency, BWP, Investment, Portland General Electric, ESS, Renewable energy

ESS Tech, Inc. (“ESS,” “ESS, Inc.” or the “Company”) (NYSE:GWH), a leading manufacturer of long-duration energy storage systems (LDES) for commercial and utility-scale applications, today announced financial results for its fourth quarter and full year ended December 31, 2023.

Key Points: 
  • ESS Tech, Inc. (“ESS,” “ESS, Inc.” or the “Company”) (NYSE:GWH), a leading manufacturer of long-duration energy storage systems (LDES) for commercial and utility-scale applications, today announced financial results for its fourth quarter and full year ended December 31, 2023.
  • At the end of 2023, ESS successfully “lifted” its first Energy Center™ (EC), a key milestone in the manufacturing process.
  • ESS will hold a conference call on Wednesday, March 13, 2024 at 5:00 p.m. EDT to discuss financial results for its fourth quarter and full year ended December 31, 2023.
  • A live webcast of the conference call will be available on ESS’ Investor Relations website at http://investors.essinc.com/ .

Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Retrieved on: 
Thursday, February 29, 2024
Neoplasm, CD47, VIVID, CD19, Exercise, Science Translational Medicine, Bone marrow, Lymphoid leukemia, Lupus nephritis, CTA, Biotechnology, Escape Room, Research and development, GLEAM, ANCA, GAAP, Sana, Insulin, Development, Immune system, Regeneration, ASH, CD22, AACR, B cell, Safety, Immunosuppression, Diabetes, Patent, IND, Insurance, Nature Biotechnology, NHL, Cancer, CLL, Contingency, Cell, NHP, Organoid, Autoimmunity, Administration, Cell Stem Cell, Patient, HIP, Nature Communications, ISSCR, C-peptide, Vaccine

The Investigational New Drug Application (IND) cleared in 4Q 2023, and Sana expects to share initial data in 2024.

Key Points: 
  • The Investigational New Drug Application (IND) cleared in 4Q 2023, and Sana expects to share initial data in 2024.
  • The Clinical Trial Application (CTA) cleared in 4Q 2023, and Sana expects initial data to be shared in the first half of 2024.
  • Non-GAAP research and development expense in 2023 excludes an expense related to the impairment of certain lab equipment and leasehold improvements, primarily due to the portfolio prioritization in the fourth quarter of 2023.
  • A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under “Non-GAAP Financial Measures.”

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, February 26, 2024
AAAAI, Injection, KIT, Research, Dermatology, Omalizumab, Eosinophilic esophagitis, B cell, Hypersensitivity, Quality of life, Work, Prurigo nodularis, Loss, DLQI, ILT4, Data, PD-1, Contingency, Inflammation, Cell, Myelocyte, Rockefeller University, Therapy, PN, Allergy, WCI, UAS7, Patient, Dermatology Life Quality Index, CSU, Survival, Congress, Disease, G&A, Itch, SRS, American Academy, Pharmaceutical industry

HAMPTON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • Celldex is currently planning two Phase 3 studies of barzolvolimab in CSU, which are expected to initiate this summer.
  • Celldex is currently planning for the initiation of a Phase 2 subcutaneous study in prurigo nodularis (PN) in early 2024.
  • The litigation settlement related loss had a ($0.26) impact on net loss per share for the twelve months ended December 31, 2023.
  • Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at December 31, 2023 are sufficient to meet estimated working capital requirements and fund current planned operations into 2026.

Skeeter’s Real Money Program Expands, Offers Payouts for More Than 160 Sanctioned Tournaments in 2024

Retrieved on: 
Wednesday, March 6, 2024
Outdoors, Fishing, Sports, Maritime, Transport, Jim Cramer, Contingency, Skeeter, Running, Auction

Skeeter will expand its Real Money contingency program in 2024 to include three levels: Real Money MAX, Real Money Grass Roots and Real Money Limited.

Key Points: 
  • Skeeter will expand its Real Money contingency program in 2024 to include three levels: Real Money MAX, Real Money Grass Roots and Real Money Limited.
  • The Real Money program rewards anglers with cash payouts for running eligible Skeeter boats with Yamaha outboards in sanctioned tournaments.
  • “The Skeeter Real Money program recognizes anglers for their loyalty and passion for the sport of competitive fishing and the Skeeter brand,” said Chris Brown, Brand Manager, Skeeter Boats.
  • For a complete list of sanctioned tournaments for 2024 and other Real Money information including official rules, and complete terms and conditions, visit Skeeter (skeeterboats.com) .

Global Helium Corp. Announces Operational Update and Shares Independent Resource Estimate From First Manyberries Well

Retrieved on: 
Wednesday, January 31, 2024
Growth, Classification, Contingency, News, Disclosure, Helium, HECO, Beaverhill Lake, Medicine Hat, Acquisition, Sale, Handbook, Development, National instrument

“I am pleased to share HECO’s first resource estimate from the McDaniel Report which demonstrates our progress to date in developing the emerging and exciting Manyberries helium trend,” continued Griffith.

Key Points: 
  • “I am pleased to share HECO’s first resource estimate from the McDaniel Report which demonstrates our progress to date in developing the emerging and exciting Manyberries helium trend,” continued Griffith.
  • Management is also exploring options to fund development of its streamlined Saskatchewan landholdings, along with existing drill-ready opportunities in Montana.
  • The effective date of the Contingent Resource estimate is December 31, 2023 and was prepared in accordance with the COGE Handbook.
  • A low estimate (“1C”) is considered to be a conservative estimate of the quantity that will actually be recovered.

Sands Point Risk Launches Managing General Agent Platform with Flagship Transaction Liability Insurance Practice

Retrieved on: 
Tuesday, January 23, 2024
Transaction, Policy, Insurance, Executive, Representation, DUAL, Contingency, TLI

JERSEY CITY, N.J., Jan. 23, 2024 (GLOBE NEWSWIRE) -- An underwriting team that is widely recognized as leaders in the Transaction Liability Insurance (“TLI”) industry is pleased to announce the launch of Sands Point Risk (“Sands Point'' or “the Company”).

Key Points: 
  • JERSEY CITY, N.J., Jan. 23, 2024 (GLOBE NEWSWIRE) -- An underwriting team that is widely recognized as leaders in the Transaction Liability Insurance (“TLI”) industry is pleased to announce the launch of Sands Point Risk (“Sands Point'' or “the Company”).
  • Sands Point is a managing general agent (“MGA”) focused on supporting expanded opportunities across financial and property and casualty insurance lines.
  • With its flagship TLI practice, Sands Point will offer a full suite of products in TLI, including Representation and Warranties, Tax Liability and Contingent Liability Insurance.
  • We will also be looking for opportunities to deliver this same level of best-in-class underwriting and customer service in other specialized insurance lines as we build out the Sands Point platform.”

nextSource Names Greg Gary VP of Workforce Solutions and Partnerships

Retrieved on: 
Monday, January 8, 2024
Growth, Contingency, Culture, Management

NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- nextSource today announced the appointment of Greg Gary as Vice President of Workforce Solutions and Partnerships.

Key Points: 
  • NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- nextSource today announced the appointment of Greg Gary as Vice President of Workforce Solutions and Partnerships.
  • Greg Gary is an innovative sales executive who brings more than 30 years of experience in sales and business development to this role where he will be responsible for leading the nextSource workforce solutions team, developing new business solutions to meet prospective client needs.
  • His career history includes sales and operational positions delivering solutions to all aspects of Contingent and Employee Workforce Acquisition and Management.
  • “I believe this instrumental role will provide high impact workforce solutions to mid-market organizations and higher education institutions across the U.S.”

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
Sale, Eye, Stargardt, Three Months, Protease, Acquisition, Research, Safety, Retinitis pigmentosa, Food, BLA, D, Commercial, Chair, CIRM, Stem cell, Patient, Secretome, FDA, CHASE, MSC, Infection, Stargardt disease, R, Nine Months, Paratriathlon, Biologics license application, Contingency, Pharmaceutical industry, Cryptocurrency, Vaccine, Clothing, Video game, Fine chemical, Life insurance, Security (finance), Drug, Alcon

ARLINGTON, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies for rare and severe diseases of the eye, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • Cash Position: As of September 30, 2023, KALA had cash and cash equivalents of $56.1 million, compared to $70.5 million as of December 31, 2022.
  • R&D Expenses: For the quarter ended September 30, 2023, research and development (R&D) expenses were $5.6 million, compared to $5.4 million for the same period in 2022.
  • Operating Loss: For the quarter ended September 30, 2023, loss from operations was $8.8 million, compared to $14.6 million for the same period in 2022.
  • The weighted average number of shares used to calculate net loss/income per share was 2.6 million for the quarter ended September 30, 2023 and 1.5 million for the quarter ended September 30, 2022.

Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Wednesday, November 8, 2023
Stem cell, Research, Insurance, CAR, Lymphoma, Patent, Leukemia, Bone marrow, Contingency, HIP, CTA, GAAP, SANA, Development, ASH, Biotechnology, Research and development, Transplant, Depreciation, Lymphoid leukemia, IST, Patient, Administration, Immunosuppression, Letter, State Administrative Expenses, Vaccine, Pharmaceutical industry, Commercial property, Cryptocurrency, Reinsurance, IND

Enrollment in the ARDENT Phase 1 study continues, and initial clinical data are expected in 2023 and more robust data expected in 2024.

Key Points: 
  • Enrollment in the ARDENT Phase 1 study continues, and initial clinical data are expected in 2023 and more robust data expected in 2024.
  • Initial HIP proof of concept data are expected in 2023 and 2024.
  • Sana is developing SC451, a hypoimmune-modified stem-cell derived pancreatic islet cell therapy for patients with type 1 diabetes.
  • A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under “Non-GAAP Financial Measures.”